Articles tagged with Cachexia
Two independent studies reveal that tumor-secreted molecule ImpL2 causes wasting syndrome, also known as cachexia, in fly cancer models. Researchers found that depletion of ImpL2 levels significantly reduced wasting in flies, suggesting new candidates for mediators of cachexia and novel therapeutic approaches.
Research reveals that white fat transforming into brown fat may stimulate weight gain and muscle strength in cancer patients suffering from cachexia. The browning process is triggered by inflammation, and anti-inflammatory therapies show promise in alleviating the condition.
Researchers have found that cachexia, associated with cancer, is triggered by the conversion of white fat to brown fat tissue, a process also studied for obesity and diabetes. Blocking inflammation-promoting cytokine IL-6 can reduce cachexia symptoms.
A new study has identified a molecular cause of cachexia and suggests a potential treatment using an anti-PTHrP antibody. The research found that blocking the effects of PTHrP can prevent wasting and improve muscle mass in mice with lung tumors.
A study by Concordia University and McGill University Health Centre found a strong link between muscle mass and strength in cancer patients with severe fatigue. The researchers suggest that specialized strength training programs could improve muscle mass and reduce fatigue, enhancing the quality of life for these patients.
A new study found that cancer-related cachexia can cause significant damage to the heart in mice with colon cancer. Researchers observed reduced heart function and changes in heart muscle structure, as well as signs of damage in the mitochondria and increased fibrous tissue.
A diabetes drug has shown promising results in slowing muscle wasting and fat loss in mice with colon cancer tumors, suggesting a potential new approach to treating cachexia, a syndrome associated with severe weight loss and muscle breakdown that can lead to cancer deaths.
Cachexia is a wasting disease that can be life-threatening if left untreated. It's often linked to an underlying disease and requires specialized care from a physician familiar with the condition.
Researchers at Oregon Health & Science University found elevated levels of leptin may be the cause of cachexia, a common complication of CKD. Blocking the MC4-R pathway in the brain may provide a novel therapeutic strategy to combat this life-threatening complication.
Researchers found that custom-designed facial implants provided excellent aesthetic postoperative outcomes for 22 patients with facial wasting syndrome. The use of high-resolution CT scans enabled precise modeling and sizing of implants, leading to stable and long-lasting results.
Researchers identified myosin heavy chain as a selective target in cancer cachexia, a condition characterized by muscle wasting. The study found that TNF-a/IFN-g-dependent loss of myosin heavy chain occurred through different mechanisms depending on the model used.
Studies by Johns Hopkins researchers found that excessive myostatin levels cause rapid muscle and fat loss in mice without affecting appetite. This discovery offers hope for new treatments for muscle-wasting diseases like muscular dystrophy and extreme weight loss associated with certain cancers, AIDS, and other conditions.
Scientists have discovered that activation of NF-kappa B prevents expression of a key regulatory protein called MyoD from replenishing muscle tissue. This finding has significant implications for treating cachexia, a syndrome that kills an estimated one third of cancer patients.
A recent study published in Annals of Internal Medicine found that testosterone administration significantly increases lean body mass and improves the quality of life in men with AIDS wasting syndrome. The treatment was shown to produce significant term benefits, making it an important new therapy for patients with this condition.